This 2019 systematic review evaluated the use of finasteride in women for treating hair disorders such as female pattern hair loss (FPHL), frontal fibrosing alopecia (FFA), and lichen planopilaris. It included various study designs—mainly observational—with treatment doses ranging from 0.5 mg to 5 mg daily and durations spanning 6 to
This 2007 randomized, placebo-controlled trial published in the European Journal of Dermatology (PMID: 17324826) assessed the safety and efficacy of 1% topical minoxidil in 280 Japanese women with androgenetic alopecia over 24 weeks. The minoxidil group showed a significant increase in non-vellus hair count (mean increase of 8.15 hairs/cm² vs.
This 2004 randomized controlled trial published in the Journal of the American Academy of Dermatology (PMID: 15034503) evaluated the efficacy and safety of 5% and 2% topical minoxidil in 381 women aged 18–49 with female pattern hair loss (FPHL) over 48 weeks. Both concentrations led to significant increases in non-vellus
This 2014 systematic review published in the American Journal of Clinical Dermatology (PMID: 24848508) provides an evidence-based update on treatments for androgenetic alopecia (AGA) in both men and women. The review concludes that oral finasteride (1 mg/day) and topical minoxidil (2% or 5%) are the most effective and well-supported options,
This retrospective observational study published in Dermatologic Therapy (PMID: 29464847) evaluated the efficacy of oral finasteride 2.5 mg/day for treating female pattern hair loss (FPHL) in premenopausal and postmenopausal women. Among the 112 patients analyzed, 65.2% showed significant improvement in hair regrowth, while 29.5% exhibited slight improvement. The study found
This randomized controlled trial evaluated the efficacy and safety of a topical solution combining 0.25% finasteride and 3% minoxidil versus 3% minoxidil alone in 30 postmenopausal women with female pattern hair loss (FPHL) over 24 weeks. The combination therapy significantly improved hair diameter (p = 0.039) and reduced serum dihydrotestosterone
This systematic review investigates the efficacy, mechanism, and safety profile of finasteride in treating female pattern hair loss (FPHL), exploring both oral and topical formulations as well as the use of dutasteride, another 5α-reductase inhibitor. The review highlights finasteride’s ability to promote hair regrowth and improve hair density by inhibiting
This randomized controlled trial evaluated the efficacy of finasteride (1 mg/day) in 137 postmenopausal women aged 41 to 60 with androgenetic alopecia (AGA) over 12 months. Despite its known mechanism of inhibiting type 2 5α-reductase to reduce dihydrotestosterone (DHT), the study found no statistically significant improvement in hair growth, slowing
This study investigates the use of dexpanthenol (DXP) as a treatment for female pattern hair loss (FPHL). The treatment showed a statistically significant improvement in the Dermatologic Life Quality Index (DLQI), with 57.1% of participants reporting satisfaction with their hair appearance. No adverse effects were noted, and laboratory results did
